Accordingly, we propose that the payment limit for a DCAPS drug be determined using the methodology described in section 1847A of the Act (also referred to as ASP methodology), or, if ASP data is not available for a particular drug, to use an alternative pricing mechanism, as described below
Still, no need to stress plenty deal with this, plus your grin can bounce back big time
However, based on quality measure submissions received for CMS' consideration during the 2023 MIPS Annual Call for Quality Measures, we are adjusting our burden estimates for the CY 2025 performance period/2027 MIPS payment year
(2) model 1 plus race/ethnicity, educational attainment, marital status, family income, region, and survey years